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Summary
Class-switch recombination (CSR) is essential for hu-
moral immunity. However, the regulation of CSR is
not completely understood. Here we demonstrate that
phosphatidylinositol 3-kinase (PI3K) actively sup-
pressed the onset and frequency of CSR in primary B
cells.Consistently,mice lacking the lipidphosphatase,
PTEN, in B cells exhibited a hyper-IgM condition due to
impaired CSR, which could be restored in vitro by spe-
cific inhibition of PI3Kd. Inhibition of CSR by PI3K
was partially dependent on the transcription factor,
BLIMP1, linking plasma cell commitment and cessa-
tion of CSR. PI3K-dependent activation of the serine-
threonine kinase, Akt, suppressed CSR, in part,
through the inactivation of the Forkhead Box family
(Foxo)of transcription factors.ReducedPI3Ksignaling
enhanced the expression of AID (activation-induced
cytidine deaminase) and accelerated CSR. However,
ectopic expression of AID could not fully overcome in-
hibitionofCSRbyPI3K, suggesting thatPI3K regulates
both the expression and function of AID.
Introduction
Class-switch recombination (CSR) and somatic hyper-
mutation (SHM) have been historically linked to the ger-
minal center (GC). Indeed, AID (activation-induced cyti-
dine deaminase), the B cell-specific factor required for
both CSR and SHM, is most highly expressed in GC B
cells (Okazaki et al., 2003). However, similar to primary
IgM, much of the class-switched IgG antibody gener-
ated early after primary immunization with T-dependent
antigens is derived from extrafollicular plasmablasts
and short-lived antibody-secreting cells (ASCs) prior to
the full establishment of GCs (Pape et al., 2003; Peak-
man and Maizels, 1998). As the immune response prog-
resses, a greater contribution of post-GC-derived long-
*Correspondence: robert@burnham.orglived ASCs secreting higher-affinity, class-switched
antibody is observed (Blink et al., 2005). These cells
ultimately take up residence in the bone marrow and
are responsible for long-term high-affinity antibody
production (Blink et al., 2005; Manz et al., 2005).
ASC versus GC cell formation result from diametrically
opposed genetic programs and differentiation path-
ways. Induced expression of the transcription factor
BLIMP1 is necessary and sufficient to initiate all of the
hallmarks of ASC differentiation including cell-cycle
withdrawal, shortened lifespan, generation of secretory
transcripts, and overall increased secretory capacity as-
sociated with endoplasmic reticulum expansion (Sha-
piro-Shelef and Calame, 2005). A major function of
BLIMP1 is to repress the transcription factors Pax5
and BCL6 (Shapiro-Shelef and Calame, 2005). Pax5 is
critical for B lineage commitment at both the progenitor
and mature B cell stage (Schebesta et al., 2002), but it
also represses the expression of genes required for an-
tibody secretion (Shapiro-Shelef and Calame, 2005).
BCL6, most highly expressed in GC B cells, is required
for GC formation in response to T-dependent antigens
(Niu, 2002). Itself a target of BLIMP1 repression, BCL6
also represses BLIMP1, creating a reciprocal negative
feedback loop (Shapiro-Shelef and Calame, 2005).
Recent evidence suggests that in addition to GC dif-
ferentiation, commitment to ASC differentiation also
precludes CSR (Hasbold et al., 2004). The contribution
of CSR to the maturation of the immune response oc-
curs at many levels; switched isotypes have greater
half-lives and tissue access than IgM, specify distinct
Fc-mediated effector functions, and display altered B
cell antigen receptor (BCR) signaling. Isotype-specific
CSR events are induced by distinct extracellular stimuli
in the presence of AID. Pax5 and another transcription
factor, E2A, are both implicated in the induction of AID
transcription, whereas BLIMP1 suppresses AID expres-
sion (Gonda et al., 2003; Sayegh et al., 2003; Sciammas
and Davis, 2004; Shaffer et al., 2002). In addition, AID
may be regulated posttranslationally (Basu et al., 2005;
Pasqualucci et al., 2006).
B cell activation in vivo is mediated by many receptors
including the BCR, costimulatory molecules, cytokine
receptors, and Toll-like receptors. However, it is not
well understood how the biochemical pathways trig-
gered by these cell-surface molecules regulate CSR
and ASC formation during the course of B cell differen-
tiation. One signaling pathway activated by all of these
receptors is the phosphatidylinositol 3-kinase (PI3K)
pathway (Deane and Fruman, 2004). Membrane-local-
ized phosphoinositides function as secondary messen-
gers of receptor signaling to regulate diverse cellular
functions. These phosphorylated lipid products are in-
ducibly generated by receptor-activated lipid kinases,
the most prominent of which is PI3K. PI3K catalyzes
the phosphorylation of phosphatidylinositol 4,5 bi-
sphosphate (PI(4,5)P2) on the 3
0 position to generate
phosphatidylinositol 3,4,5 trisphosphate (PIP3). The
class IA PI3Ks are heterodimers composed of a regula-
tory subunit (p85, p55, or p50) and a catalytic subunit
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of PI3Kd, the major isoform activated in B cells down-
stream of the BCR (Clayton et al., 2002; Jou et al.,
2002; Okkenhaug et al., 2002). The lipid phosphastase
PTEN directly antagonizes PI3K activity by dephosphor-
ylating PIP3 to regenerate PI(4,5)P2.
Two major pathways are activated downstream of
PI3K in B cells, the Btk (Bruton’s tyrosine kinase) path-
way and the PDK1 (3-phosphoinositide-dependent
kinase 1)-dependent Akt (also known as protein ki-
nase B, PKB) pathway (Cantrell, 2002; Schaeffer and
Schwartzberg, 2000). Btk, PDK1, and Akt are recruited
to the plasma membrane via PIP3 binding pleckstrin ho-
mology domains, and both the Btk and Akt pathways
contribute to the survival and proliferation of activated
B cells. However, the means by which these two path-
ways effect proliferation and survival are largely distinct.
The major target of Btk activation is PLCg (phospholi-
pase C g), resulting in Ca2+ flux and PKC (protein kinase
C) activation (Forssell et al., 1999; Fruman et al., 2000).
Activation of PDK1 results in the phosphorylation and
activation of Akt and other AGC kinases (containing pro-
tein kinase A, protein kinase G, and protein kinase C
families), that collectively regulate cellular proliferation,
growth, metabolism, and survival (Mora et al., 2004).
The involvement of Akt in cellular survival and prolifera-
tion may be due largely to its phosphorylation-depen-
dent inactivation of the Forkhead Box (Foxo) family of
transcription factors, which results in the silencing of
Foxo target proteins that promote cell-cycle arrest and
apoptosis (Greer and Brunet, 2005; Yusuf et al., 2004).
The importance of regulated PI3K activity in B cells is
exemplified by mice deficient for PI3K or PTEN. Mice de-
ficient for the individual regulatory or catalytic subunits
of PI3K have defects in B cell development and immune
responses (Deane and Fruman, 2004). Conversely, we
and others have found that mice carrying a B cell-spe-
cific deletion of PTEN have increased numbers of pe-
ripheral B cells, but still exhibit impaired immune re-
sponses (Anzelon et al., 2003; Suzuki et al., 2003).
To date, much of the focus on PI3K signaling in B cells
has been on mitogenic signaling by the BCR. However,
a molecular and biochemical understanding of how
PI3K governs other aspects of B cell differentiation is
lacking. Here we demonstrate that PI3K inversely regu-
lates ASC formation and induction of CSR by activating
Akt and repressing Foxo function.
Results
Impaired PIP3 Hydrolysis Blocks CSR
We and others have generated mice deficient for PTEN in
B cells (bPten2/2) (Anzelon et al., 2003; Suzuki et al.,
2003), which produce IgM-dominated immune responses
reminiscent of the hyper-IgM (HIGM) condition associ-
ated with defects in T cell help or CSR (Durandy et al.,
2005; Suzuki et al., 2003). However, although we noted
the presence of GCs in bPten2/2 mice immunized with
sheep red blood cells (SRBC) (Anzelon et al., 2003), others
failed to find evidence of GC formation in mice immunized
with the hapten-carrier NP-CGG (Suzuki et al., 2003).
To determine whether GC formation in bPten2/2 mice
was unique to SRBC immunization, mice were immu-
nized with the hapten-carrier TNP-OVA in alum andanalyzed 8 and 14 days (d8, d14) after immunization.
Consistent with previous findings (Suzuki et al., 2003),
measurement of antigen-specific antibody titers by
ELISA revealed higher amounts of IgM and lower
amounts of IgG in sera from bPten2/2 mice (see
Figure S1A in the Supplemental Data available online).
Immunohistochemistry of frozen spleen sections from
immunized mice revealed increased numbers of brightly
staining IgMhi ASC in bPten2/2 mice at d8 and d14
(Figure 1A). In contrast, although a few IgGhi ASCs could
be identified in bPten2/2 spleen sections at d8, their fre-
quency was extremely low and did not increase mark-
edly over time (Figure 1A). By comparison, brightly
staining IgGhi ASCs were identified in the red pulp of
wild-type (WT) mice at d8 and d14 after immunization.
Consistent with our previous findings with SRBC immu-
nizations (Anzelon et al., 2003), we observed well-
formed GCs in bPten2/2 mice (Figure 1A), indicating
that the lack of IgG+ ASCs in these mice is not partially
due to the absence of GCs. These effects (CSR, ASC,
and GC formation) were not specific to the antigen or ad-
juvant used; similar results were obtained with different
T-dependent antigen and adjuvant pairs (TNP-OVA in
alum or NP-KLH in CFA or RIBI; Figure S1B). Given these
findings, our focus shifted to the examination of CSR
and ASC differentiation in bPten2/2 mice.
To assess CSR and ASC formation more quantita-
tively, splenocytes from d14 immunized mice were ana-
lyzed by flow cytometry (FACS) for expression of IgM,
IgG, and the ASC marker, Syndecan 1 (Syn1). Consistent
with the histology, FACS revealed that bPten2/2 mice
generated very few IgG+ cells (Figure 1B). When the phe-
notype of the Syn1+ cells was assessed, many IgM+ and
IgM2 ASCs were observed in WT mice, whereas
bPten2/2 mice produced more IgM+ ASCs, but much
fewer IgM2 ASCs. To determine whether the few IgM2
ASCs observed in bPten2/2 mice contained cells that
had switched to an isotype other than IgG (i.e., IgA or
IgE), ASC formation was analyzed in an independent co-
hort of mice with the inclusion of a stain for IgA and IgE.
Similar to what was observed for IgG, whereas IgA+
ASCs were detected in the IgM2 ASC population in WT
mice, virtually no IgA+ ASCs were observed in bPten2/2
mice (Figure S1C). IgE+ ASCs were not detected in
either WT or bPten2/2 mice (data not shown). Lastly,
quantitative analysis of antigen-specific ASC formation
by ELISPOT confirmed the enhanced formation of IgM-
secreting ASCs and decreased formation of IgG-secret-
ing ASCs in bPten2/2 mice (Figure 1C). These data sug-
gest that the sustained presence of PIP3 brought on by
the loss of PTEN promotes the formation of IgM-secret-
ing ASCs while preventing CSR to other isotypes in
response to a T-dependent antigen.
Because in vivo analyses of T-dependent responses
can be influenced by B cell-extrinsic variables (e.g.,
T cell priming or activation), we analyzed ASC formation
and CSR under defined in vitro conditions. Splenic B
cells were stimulated with LPS (lipopolysaccharide),
LPS+IL-4, or aCD40+IL4 and assessed 3 days (d3) later
for ASC formation and CSR by FACS. bPten2/2 B cells
failed to undergo CSR to IgG3 or IgG1 in the presence
of LPS or LPS+IL-4, respectively (Figure 1D). However,
the formation of ASCs, identified as B220loSyn1hi, was
enhanced in the absence of PTEN. aCD40+IL-4 did not
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547Figure 1. bPten2/2 B Cells Display Enhanced ASC Formation, but Fail to Undergo CSR
(A) Spleens from mice immunized with TNP-OVA were stained for ASCs (left) with anti-IgM (red) or a cocktail of anti-IgG1, -IgG2a-b, and -IgG3
(blue); or with PNA (peanut agglutinin, blue) for GCs within B cell (B220, brown) follicles (right) on d8 and d14 after immunization. IgG+ ASC clus-
ters are indicated by arrows.
(B) Splenocytes from the same mice were stained for IgM and IgG (cocktail of anti-IgG1, -IgG2a-b, and -IgG3) and Syndecan1 (Syn1) expression
on IgD-, CD3-, CD11b-negative cells as indicated by the starting gate. The mean6 SD of the IgG+ populations; and the IgM+, IgM2IgG2, and IgG+
populations within the B220int-loSyn1+ ASC gate for three mice in each group is shown. Data are representative of at least three experiments of
nR 3 mice each.
(C) ELISPOT analysis (mean 6 SD) of antigen-specific ASCs from mice immunized 14 days prior with TNP-OVA (n = 4 mice each).
(D) Purified B cells cultured with the indicated mitogens were stained for B220, Syn1, and isotype-specific IgG as indicated to measure ASC for-
mation (gated B220loSyn1hi population) and CSR (gated CFSEloIgG+ population). Values indicate the percentage of cells in the gated population.
Data are representative of five or more independent experiments.induce marked CSR to IgG1 in either WT or bPten2/2 B
cells, but did cause enhanced ASC differentiation in the
absence of PTEN. Consistent with our in vivo findings,these data suggest that unchecked PIP3 production
supports the development of ASCs while suppressing
CSR.
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in WT B Cells
Because elevated amounts of PIP3 inhibited CSR in
bPten2/2 B cells, we reasoned that inhibition of induced
PI3K activity would promote CSR. To test this hypothe-
sis, WT B cells were labeled with the cell division
tracking dye carboxyfluorescein diacetate (CFSE) and
cultured under the conditions described above in
the absence or presence of the pan-PI3K inhibitor,
LY294002, or the PI3Kd-specific inhibitor, IC87114
(Puri et al., 2004; Sadhu et al., 2003). A titration curve
was performed to determine the inhibitor concentra-
tions that had limited effects on survival and prolifera-
tions (Figures S2 and S5). These concentrations (5 mM
for LY294002 and 10 mM for IC87114) were used in all
subsequent experiments. Analyses of equal numbers
of live cells showed that inclusion of LY294002 in LPS-
or LPS+IL-4-stimulated cultures resulted in enhanced
CSR to IgG3 or IgG1, respectively, compared to un-
treated cells receiving the same stimuli (Figure 2A).
When IC87114 was included in cultures stimulated
with LPS, LPS+IL-4, or aCD40+IL-4, a greater increase
in the amount of CSR to IgG3 or IgG1, respectively,
was observed relative to untreated or LY294002-treated
cultures (Figure 2A). An analysis of multiple experiments
showed that increased CSR in cultures treated with PI3K
inhibitors compared to untreated cultures was highly re-
producible and statistically significant (Figure 2B). Vari-
ations in cell density, mitogen concentration, source of
IL-4 (recombinant or culture supernatant), and switching
to nontargeted loci were also tested to verify the gener-
ality of these findings (Figure S3). While we cannot rule
out that LY294002 had more widespread effects that
negatively regulated CSR, which could account for the
difference in the effects of the two inhibitors, it is more
probable that this difference was due to increased toxic-
ity associated with LY294002 compared to IC87114
(data not shown). At the concentration used, LY294002
strongly inhibits PI3Kd but also affects PI3Kb; whereas
the chosen concentration of IC87114 specifically affects
PI3Kd (Sadhu et al., 2003). Altogether these data indi-
cate that PI3Kd is the predominant class I PI3K isoform
involved in regulating CSR. In addition to their profound
effect on CSR, the selected concentrations of PI3K in-
hibitors also impaired ASC formation both phenotypi-
cally as measured by FACS (Figure 2A) and functionally
as measured by ELISPOT (Figure S4), suggesting that
increased CSR may come, in part, at the expense of
ASC formation.
Because treatment of stimulated cultures with
IC87114 did result in a generalized decrease in cell sur-
vival, it was necessary to ascertain whether the differ-
ences in CSR and ASC formation observed in IC87114-
treated cultures were due to selective survival or death
of the class-switched or ASC populations. When cellular
viability in d3 cultures was measured by 7AAD staining,
the data showed that there was no evidence for a selec-
tive decrease in ASC viability in inhibitor-treated cul-
tures that could account for the decrease in ASC forma-
tion, nor selective survival of class-switched cells to
account for the increase in CSR (Figure S5).
CSR is targeted by cytokine-induced transcriptional
activation of specific heavy chain constant regions
(Stavnezer, 1996). To determine whether enhancedCSR in the presence of PI3K inhibitors was applicable
to other isotypes or stimuli, WT B cells were stimulated
with LPS or LPS+TGF-b (Figure S6) or LPS+IFN-g (data
not shown) in the absence or presence of IC87114.
FACS analyses revealed enhanced CSR to IgG2a or
IgG2b (LPS, LPS+TGF-b, LPS+IFN-g) and IgA
(LPS+TGF-b) in the presence of IC87114. Suppression
of CSR in the absence of PTEN does not affect the pro-
duction of sterile transcripts from the heavy chain locus
(Suzuki et al., 2003, and our data not shown), so these
data indicate that PI3K activity is not acting at the level
of locus accessibility, but is involved in regulating the
central process of CSR.
Inhibition of PI3Kd Increases the Rate and Frequency
of CSR
The appearance of class-switched cells and ASCs oc-
curs in a division-linked manner that does not depend
on the length of time in cycle (Hasbold et al., 1998,
2004; Hodgkin et al., 1996). To ascertain the reason for
increased numbers of class-switched cells in cultures
treated with IC87114, the percent IgG+ cells per genera-
tion was determined (Figure 2C). In untreated, LPS-, or
LPS+IL-4-stimulated cultures, substantial numbers of
switched cells were not apparent until the third or fourth
division and did not occur to a substantial degree in un-
treated aCD40+IL-4 cultures. In marked contrast, cul-
tures treated with IC87114 produced large numbers of
switched cells as early as the first division cycle and
steadily increased with each subsequent division
(Figure 2C, Figure S3). Similar results were observed
when recombinant IL-4 was used instead of IL-4-con-
taining supernatant (Figure S3). The preponderance of
switched cells observed at later divisions is likely due
to the additive presence of both newly switched cells
at a particular division cycle as well as the persistence
of cells that had undergone CSR in a previous cell cycle
and continued to divide (Hasbold et al., 2004).
Because PI3K seemed to regulate CSR, we wished to
determine whether decreasing PI3K activity in stimu-
lated bPten2/2 B cells would restore CSR. When CSR
was assessed in bPten2/2 B cell cultures stimulated
with LPS, LPS+IL-4, or aCD40+IL-4 in the presence of
LY294002 or IC87114, we found that CSR was partially
restored (Figure 3). These findings indicate that the in-
ability of bPten2/2 B cells to undergo CSR is not a result
of altered in vivo differentiation, but due to active sup-
pression of the class-switch machinery in the presence
of sustained PIP3. These data strongly support the hy-
pothesis that a reduction in PIP3 or reduced PI3K activity
is a necessary prerequisite for initiation of the CSR pro-
gram during B cell differentiation.
Inhibition of CSR by PI3K Is Partially Dependent
on BLIMP1
The transcription factor BLIMP1 is absolutely required
for ASC development, and gene expression arrays sug-
gest that it may repress AID expression and thus CSR
(Sciammas and Davis, 2004; Shaffer et al., 2002). Our
finding that PI3K inhibitors promote CSR and suppress
ASC formation in vitro suggested that BLIMP1 and
PI3K have a functional relationship. To explore this pos-
sibility, B cells from mice carrying a B cell-specific dele-
tion of BLIMP1 (bPrdm12/2) were stimulated in the
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(A) WT B cells cultured with the indicated mitogens in the absence or presence of the pan-PI3K inhibitor, LY294002, or the PI3Kd-specific inhib-
itor, IC87114, were stained for B220, Syn1, and isotype-specific IgG as indicated to identify class-switched cells (B220+IgG+, left) and ASCs
(B220loSyn1+, right). Values indicate the percentage of cells in the gated population. Data are representative of 4–10 independent experiments.
(B) Average fold increase (mean 6 SD) in CSR of PI3K inhibitor-treated cultures over untreated cultures of 4–10 independent experiments. p
values are indicated by asterisks (*p < 0.005, **p < 0.05).
(C) Division-linked CSR was assessed in WT B cells cultured with the indicated mitogens in the absence or presence of IC87114. Graphs show the
proportion of isotype-specific IgG+ cells present in each cell division. Each division peak was gated with the proliferation tool in FlowJo (Trees-
tar), and a representative gating profile for WT B cells stimulated with LPS+IL-4 in the presence of IC87114 is shown. Data are representative of
4–10 independent experiments.absence or presence of IC87114 and analyzed for CSR
and ASC formation. As previously reported (Shapiro-
Shelef et al., 2003), ASC development was completely
blocked in cultures of bPrdm12/2 B cells (data not
shown). However, stimulation of bPrdm12/2 B cells
with LPS or LPS+IL-4, even in the absence of IC87114,
resulted in increased CSR (Figure 4A). To determine
whether suppression of CSR by PI3K was dependenton BLIMP1 expression, CSR was assessed in B cells
lacking both PTEN and BLIMP1 (bPten2/2bPrdm12/2).
The absence of BLIMP1 resulted in a partial restoration
of CSR in B cells that also lacked PTEN (Figure 4B). To-
gether with the observation that IC87114 enhanced CSR
in bPrdm12/2 B cells to levels that surpassed those
achieved in IC87114-treated WT B cells (Figure 4A),
these data suggest that BLIMP1 activation downstream
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the absence of PTEN.
The ability of BLIMP1 deficiency alone to increase
CSR correlated with culture conditions that promote
the generation of ASCs in WT cells. These data are con-
sistent with the observation that WT B cells cultured in
the presence of IC87114 have a decrease in ASC gener-
ation (see Figure 2). These data suggest that under con-
ditions where an uncommitted, activated precursor is
prevented (chemically or genetically) from becoming
an ASC, those cells are more prone to undergo CSR.
In support of this hypothesis, when CSR was analyzed
with respect to division number, the combined effect
of BLIMP1 deficiency and PI3Kd inhibition was additive
in cultures stimulated with LPS or LPS+IL-4 (Figure 4C).
These results imply that BLIMP1 expression contributes
to PI3Kd-dependent inhibition of CSR by coordinating
ASC commitment (see Discussion).
Inhibition of CSR by PI3K Occurs via Akt-Mediated
Inhibition of Foxo Transcription Factors
Akt is a central downstream target of PI3K; therefore,
we wished to determine whether it contributed to
PI3K-mediated inhibition of CSR. Immunoblot analysis
of WT B cells stimulated with LPS+IL-4 in the presence
of IC87114 showed strong inhibition of Akt activation
at 1 hr poststimulation that was sustained to 24 hr
Figure 3. Inhibition of PI3K Activity Partially Restores CSR in
bPten2/2 B Cells
Isotype-specific CSR and ASC formation were assessed in bPten2/2
B cells cultured with the indicated mitogens in the absence or pres-
ence of LY294002 or IC87114. WT B cells stimulated in the absence
of inhibitors are shown for comparison. Values indicate the percent-
age of cells in the gated population. Data are representative of four
independent experiments.(Figure 5A). To directly address the role of Akt in PI3K-
mediated inhibition of CSR, retroviral gene transfer
was used to express constitutively active Akt (myrAKT,
membrane targeted) in WT B cells prestimulated with
LPS+IL-4. Where noted, IC87114 was added to cells im-
mediately after infection. Cells were harvested 2 days
after infection, and infected cells (GFP+) were analyzed
for CSR and ASC formation (Figure 5B). Strikingly, myr-
AKT strongly blocked CSR and caused a modest in-
crease in LPS+IL-4-induced ASC formation. Moreover,
myrAKT also blocked enhanced CSR promoted by
IC87114, consistent with the PIP3-independent target-
ing of myrAKT to the membrane. Quantitative RT-PCR
(QT-PCR) of GFP+ sorted cells revealed that inhibition
of CSR by myrAKT correlated with the reduction of
AID message.
To further elucidate the Akt-dependent pathway lead-
ing to inhibition of CSR, we focused on the Foxo family
of transcription factors that are negatively regulated by
Akt phosphorylation (Greer and Brunet, 2005). Mutation
of the regulatory serine and threonine residues in Foxo
proteins results in a constitutively nuclear protein that
can no longer be phosphorylated and inactivated by
Akt (Greer and Brunet, 2005). Both Foxo1 and Foxo3a
are expressed at demonstrable amounts in primary B
cells; however, Foxo1 appears to be more abundant
(Yusuf et al., 2004). To determine whether the Foxo pro-
teins were responsible for promoting CSR when PI3K-
Akt activity are attenuated, WT and bPten2/2 B cells
were infected with retroviruses expressing wild-type
(Foxo1) or constitutively nuclear Foxo1 (Foxo1(A3)),
and infected cells (Thy1.1+) were analyzed for CSR and
ASC formation (Figure 5C). Expression of wild-type
Foxo1 did not induce higher CSR in either WT or
bPten2/2 B cells. However, consistent with the involve-
ment of Akt in the inhibition of CSR downstream of PI3K
activation, Foxo1(A3) caused a small increase in CSR in
WT B cells and a significant increase in CSR in bPten2/2
B cells. Further, Foxo1(A3) decreased ASC formation in
both WT and bPten2/2 B cell cultures (Figure 5C). Inter-
estingly, Foxo1(A3) caused an even greater increase in
CSR in bPten2/2 B cells treated with IC87114 than was
observed in similarly treated WT B cells. Consistently,
QT-PCR analyses of infected cells showed strong induc-
tion of AID message in cells infected with Foxo1(A3)-
expressing virus. These data suggest that PI3K activity
supports ASC differentiation and inhibits CSR in un-
committed precursors via Akt activation and nuclear
exclusion of Foxo1 resulting in poor induction of AID
expression.
It has been proposed that BCL6 is a downstream tar-
get of Foxo3a and Foxo4 (Fernandez de Mattos et al.,
2004; Tang et al., 2002). We have shown that forced ex-
pression of constitutively nuclear Foxo1 is able to re-
press ASC formation and promote CSR (Figure 5C). To
determine whether BCL6 acts downstream of Foxo1 to
promote CSR, WT and bPten2/2 B cells were infected
with retroviruses expressing BCL6 (Figure 5D). Ectopic
BCL6 strongly inhibited ASC formation in response to
LPS+IL-4 as previously demonstrated (Reljic et al.,
2000; Tunyaplin et al., 2004); however, no enhancement
of CSR was observed in WT or bPten2/2 B cells, sug-
gesting that BCL6 does not promote CSR even though
it is required for GC formation (Niu, 2002). Hence,
PI3K and Terminal B Cell Differentiation
551Figure 4. Inhibition of PI3Kd in bPrdm12/2 B Cells Causes Synergistic Enhancement of CSR
(A) Isotype-specific CSR was assessed in WT and bPrdm12/2 B cells cultured with the indicated mitogens in the absence or presence of
IC87114 as described previously. Values indicate the percentage of cells in the gated population. Data are representative of four independent
experiments.
(B) CSR in B cells deficient for both PTEN and BLIMP1 (bPten2/2bPrdm12/2). A representative FACs profile is shown with percentage of cells in
the gated population indicated. Bar graph shows the mean6 SD of percent IgG+ compared to percent IgG+ observed in WT B cells (set to 100%
in each experiment) for three independent experiments. p value for bPten2/2 compared to bPten2/2bPrdm12/2 is indicated on the graph.
(C) Graphs show the proportion of IgG+ cells present in each cell division for the experiment shown in (A). Division gating was performed as
shown in Figure 2C. Data are representative of four independent experiments.although suppression of ASC development by Foxo1
may be due to BCL6 expression, increased CSR by
Foxo1 is not.Elevated PI3K Activity Affects AID Function
We showed that pharmacologic inhibition of PI3K activ-
ity in bPten2/2 B cells partially restored CSR (Figure 3).
Immunity
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(A) Akt activation was assessed in purified B cells stimulated with LPS+IL-4 in the absence or presence (+) of IC87114 for the indicated times. The
bar graph shows the amount of phospho-Akt normalized to total Akt in each sample.
(B–D) B cells were infected with bicistronic retroviruses expressing (B) constitutively active Akt (myrAKT), (C) wild-type Foxo1 (Foxo1) or con-
stitutively nuclear Foxo1 (Foxo1(A3)), (D) BCL6, or empty virus control (MIG or MIT). After infection, cells were cultured for 2 additional days
in the absence or presence of IC87114, after which CSR and expression of ASC markers were assessed in infected cells (GFP+, myrAKT, or
BCL6; Thy1.1+, Foxo1, or Foxo1(A3)). Bar graphs show the mean 6 SD of the percent IgG1+ (or B220loSyn1hi ASCs) of myrAKT-, Foxo1-,
Foxo1(A3)-, or BCL6-infected cells compared to WT cells infected with empty virus cultured in the absence of inhibitor (set at 100% in each ex-
periment) for at least six independent experiments (B, C) or two independent experiments (D). p values for the bracketed populations are indi-
cated on each graph. Typical infection efficiency for all viruses was 30%–70%. Relative AID message levels were determined by QT-PCR on
sorted GFP+ (B) or Thy1.1+ (C) infected cells, and graphs are representative of three experiments. Untrd, untreated.QT-PCR of RNA from stimulated bPten2/2 B cells
showed impaired AID expression (see Figure 5C), con-
sistent with previous work (Suzuki et al., 2003),
whereas inhibition of PI3K caused an increase in AID
expression. To determine whether impaired CSR in
bPten2/2 B cells is solely due to negative regulation
of AID expression by PI3K, AID was ectopically ex-pressed in stimulated bPten2/2 B cells by retroviral in-
fection (Figure 6A). Ectopic expression of AID in
bPten2/2 B cells resulted in increased CSR to levels
similar to those observed in bPten2/2 B cells infected
with empty virus (TAC) and treated with IC87114, sug-
gesting that PI3K is regulating CSR by controlling AID
expression. However, these levels were still lower
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(A) WT and bPten2/2B cells were infected with AID-expressing retrovirus or empty virus control (TAC) and recultured in the absence or presence
of IC87114 for 3 days. Infected cells identified by huCD25a expression were assessed for CSR and ASC formation. A representative FACS plot is
shown with the percentage of cells in the gated population indicated, and the bar graph shows the mean6 SD of the percent IgG1+ AID-infected
cells compared to WT cells infected with empty virus cultured in the absence of inhibitor (set at 100% in each experiment) for four independent
experiments. p values for the bracketed populations are indicated on each graph.
(B) WT B cells were infected with both myrAKT (see Figure 5B) and AID-expressing retroviruses and recultured in the absence or presence of
IC87114 for 3 days. Doubly infected cells were identified by dual expression of GFP (myrAKT) and huCD25a (AID) as indicated for the MIG-
AID sample and assessed for CSR. Empty virus controls are MIG (for myrAKT) and TAC (for AID). A representative FACs profile for untreated
cells is shown with the percentage of cells in the gated population indicated. The bar graph shows the mean6 SD of the percent IgG1+-infected
cells compared to WT cells infected with both empty viruses (MIG-TAC) cultured in the absence of inhibitor (set at 100% in each experiment) for
three independent experiments. p values are indicated on each graph. Infection efficiency was typically 15%–40%. IC8, IC87114.than those achieved in WT B cells infected with empty
virus and stimulated in the absence of inhibitor. Fur-
thermore, when bPten2/2 cells infected with the AID-
expressing virus were allowed to recover in the pres-
ence of IC87114, an additional enhancement of CSR
was observed. These data suggest that expression of
AID does not completely restore CSR in the presence
of high PI3K activity, implying that PI3K may also inhibit
AID function in addition to regulating its expression.To test this hypothesis, WT B cells stimulated with
LPS+IL-4 or aCD40+IL-4 (Figure 6B and data not
shown) were doubly infected with constitutively active
Akt (myrAKT) and AID-expressing retroviruses. Analy-
sis of CSR showed that cells containing both myrAKT
and AID displayed increased CSR compared to cells in-
fected with AKT alone, but significantly lower levels of
CSR compared to cells infected with AID alone. These
data support our hypothesis that sustained PI3K-Akt
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tional and posttranscriptional levels.
Discussion
Primary antibody responses are dominated by low-affin-
ity IgM that provides neutralizing activity to limit dissem-
ination of toxic or infectious agents. As clonal expansion
proceeds, some B cells undergo ASC differentiation,
while others undergo CSR or form GCs. Class-switched
antibody is a major component of primary antibody re-
sponses as the humoral response progresses and con-
tributes more effectively to host defense through diver-
sified effector functions, and later post-GC through
enhanced affinity. The necessity for CSR and effective
immune responses is underscored by deficiencies
noted in patients with HIGM syndrome. These patients
have increased susceptibility to infections resulting in
part from an inability to undergo CSR (Etzioni and
Ochs, 2004). Our data support the view that PTEN defi-
ciency in B cells may also represent a HIGM condition.
Thus, an interesting prospect is that cases of HIGM
that currently have no genetic classification may carry
mutations in genes that regulate PI3K activity.
It has been proposed that ASC formation and CSR are
regulated by stochastic mechanisms at the level of the
individual cell (Hasbold et al., 2004), and while terminal
gene targets required for these processes have been
identified (BLIMP1, BCL6, and AID), the signaling path-
way(s) involved are largely unknown. We show here
that commitment to ASC formation or CSR is intimately
linked to the degree of PI3K activation elicited by sur-
face receptors. Inhibition of PI3Kd strongly promotes
CSR by increasing the generation of switched cells at
earlier cell divisions. These data support the hypothesis
that repression of CSR and simultaneous promotion of
ASC formation by strong PI3K activity prevents prema-
ture CSR during the early stages of antigenic encounter
when antigen load is high and BCR-dependent clonal
expansion is vigorous. Such a mechanism would allow
for the successive generation of IgM-secreting ASCs
to promote initial clearance of antigen. Indeed, it has
been shown that multivalent crosslinking of the BCR
(mimicked in vitro with anti-IgM (Fab’)2 fragments)
causes a delay in CSR in response to CD40L+IL-4 stim-
ulation (Rush et al., 2002). Based on our data, we pro-
pose that this effect is caused by strong PI3K activation
through the combined contributions of the BCR, CD40,
and IL-4R (IL-4 receptor). As antigenic load decreases,
changes in surface receptor signaling resulting in re-
duced PI3K signaling together with depletion of PIP3,
presumably by PTEN, causes an overall reduction in
PIP3 levels, allowing for CSR and the generation of
more specialized class-switched ASC effectors.
By using retroviral gene transfer, we demonstrate that
regulation of CSR and ASC formation by PI3K occurs via
the PI3K/Akt/Foxo signaling axis. Constitutively ac-
tive Akt (myrAKT) inactivates Foxo transcription factors
and strongly suppresses CSR, whereas constitutively
nuclear Foxo1 (Foxo1(A3)) enhances CSR and sup-
presses ASC formation. A potential mechanism for sup-
pression of ASC formation by Foxo proteins is the acti-
vation of BCL6, a target of Foxo transcription factors
in other systems (Fernandez de Mattos et al., 2004;Tang et al., 2002). Since BCL6 expression appears to
be confined to the GC, such a mechanism may operate
only in the late follicular response. However, enhanced
ASC formation by BCL62/2 B cells in vitro suggests
that a regulatory role for BCL6 in the extrafollicular
ASC response cannot be ruled out (Tunyaplin et al.,
2004). In addition, our data show that while ectopic
BCL6 is sufficient to suppress ASC development, it
does not induce or enhance CSR in WT B cells regard-
less of PI3K activity. Hence, BCL6 is likely not the
Foxo target in B cells that induces CSR, providing fur-
ther support that CSR is not a BCL6-driven process.
It was recently reported that the expression of AID is
regulated by cell division and that its overexpression in
B cells from AID transgenic animals results in the ap-
pearance of switched cells at a higher frequency and
earlier cell divisions (Rush et al., 2005). These findings
are reminiscent of what we observe here with the
PI3Kd inhibitor, implying that PI3K regulates division-
linked CSR by controlling the expression of AID. How-
ever, while forced expression of constitutively nuclear
Foxo1 caused a modest rescue of CSR in bPten2/2 B
cells, when combined with reduced PI3K activity, a syn-
ergistic effect on CSR was observed. Furthermore, ex-
pression of AID in bPten2/2 B cells resulted in a much
stronger rescue of CSR when combined with inhibition
of PI3K activity, and expression of active Akt decreased
CSR induced by ectopic AID expression in WT B cells.
Together, these data suggest that PI3K is acting to sup-
press CSR by interfering with AID transcription as well
as its function.
There are many points at which PI3K activity could be
regulating the function of AID in CSR. AID contains a nu-
clear export sequence (NES) that prevents its nuclear
accumulation (McBride et al., 2004; Shinkura et al.,
2004). However, forced nuclear accumulation of AID
did not result in increased CSR (McBride et al., 2004),
implicating a requirement for other limiting factors.
Along these lines, CSR and SHM require separate do-
mains of AID and the recruitment of specific cofactors
(Barreto et al., 2003; Shinkura et al., 2004; Ta et al.,
2003), and AID activity is dependent upon phosphoryla-
tion by protein kinase A (Basu et al., 2005; Pasqualucci
et al., 2006). Hence, PI3K could be directly affecting
AID by regulating its nuclear localization, phosphoryla-
tion, and/or association with cofactors, and/or by regu-
lating the nuclear localization and/or expression of co-
factors or upstream effectors.
Our data suggest that PI3K acts to suppress CSR in
both a BLIMP1-dependent and BLIMP1-independent
manner. This hypothesis is supported by the fact that
the absence of BLIMP1 in bPten2/2 B cells partially re-
stores CSR. One explanation as to why the level of res-
cue in these cells is not higher is that these cells retain
a high level of activated Akt acting to suppress CSR in
a PI3K-dependent, likely Foxo1-dependent, and
BLIMP1-independent manner. These data are consis-
tent with the observation that increased CSR observed
in bPrdm12/2B cells can be further augmented by inhib-
iting PI3K. Under conditions that efficiently promote
ASC development, BLIMP1 expression is sufficient to
promote the early entry of some uncommitted precur-
sors toward ASC formation, suppressing further CSR
(Hasbold et al., 2004; Sciammas and Davis, 2004;
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the number of uncommitted precursors is increased
(due to the unavailability of the ASC pathway), thereby
increasing the potential frequency of cells available to
undergo CSR. Our data suggest that enhanced CSR
due to inhibition of PI3K is the result of increased recruit-
ment of undifferentiated precursors into the CSR path-
way, in part due to the inhibition of ASC formation.
We propose that during the early stages of the anti-
body response, ASC formation is promoted and CSR
is suppressed in uncommitted precursors by high PI3K
activity. Suppression of CSR by PI3K is dependent on
Akt activity and inhibition of Foxo family transcription
factors. As the local antigenic load decreases, PI3K ac-
tivity is reduced and Foxo proteins are released from
Akt-mediated repression. Activation of Foxo proteins re-
sults in the repression of ASC development, potentially
through inhibition of BLIMP1, allowing the expression
and activation of AID to enable CSR. Subsequently,
class-switched cells re-enter the differentiation cycle
and can reinitiate the ASC genetic program or undergo
another round of CSR. Whether the signals that trigger
ASC formation of a class-switched cell are the same
as those required for ASC formation of a naive B cell
(i.e., high PI3K activity) remains to be determined.
Experimental Procedures
Mice
B cell-specific deletion of PTEN and BLIMP1 and genotyping has
been described previously (Anzelon et al., 2003; Shapiro-Shelef
et al., 2003). WT littermate controls were used whenever possible
to control for background variation. No differences were observed
between CD19+/+ orCD19cre+/2 control animals. Experiments utiliz-
ing only WT animals were performed with 129 Sv/J mice bred in the
BIMR animal facility. All experiments were performed on animals 8–
20 weeks old and approved by the BIMR Animal Review Committee.
Immunizations and Immunohistochemistry
Mice were immunized by intraperitoneal injection with 50 mg of
TNP12OVA (Biosearch Technologies) in alum (Imject, Pierce). Frozen
sections or spleens from immunized animals embedded in OCT
compound (Sakura, Finetek) were stained as described in Qian
et al. (2004). Images were captured at 53 magnification.
ELISPOTS were performed as described previously (Shapiro-
Shelef et al., 2003), with the exception that both IgM and IgG ASCs
were differentially detected in the same well with anti-mouse IgM
IR700 and anti-mouse IgG IR800 (Rockland Immunochemicals)
and the Odyssey Infrared Imaging System (Licor).
Cell Culture
After hypotonic lysis of RBCs with ACK buffer, splenic B cells were
purified by negative selection with anti-CD43 magnetic beads (Milte-
nyi Biotec, >90% purity), labeled with 2.5 mM CFSE (Molecular
Probes), and cultured in complete RPMI 1640 at 2 3 106/ml for 3
days unless otherwise noted. Mitogen concentrations were: LPS
(Sigma) 20 mg/ml, anti-CD40 (IC10 clone, eBiosciences) 4 mg/ml,
IL-4 from cell culture supernatant 1:50 dilution. For inhibitor studies,
LY294002 (5 mM in DMSO, Calbiochem) or IC87114 (10 mM in DMSO,
ICOS Corporation) was added once at the beginning of the culture
period unless otherwise noted. In some experiments, DMSO was
added to ‘‘untreated’’ controls (1:1000 dilution). No differences be-
tween cells treated with or without DMSO alone were observed
(data not shown).
Flow Cytometry
Cells were preincubated with FcBlock (anti-CD16/32) prior to
staining with biotinylated IgG1, IgG2a-b, IgG3, or Syndecan1
(Syn1) antibody followed by incubation with streptavidin (SA)-conju-
gated PerCP-Cy5 or APC, anti-Syn1-PE or -IgA-PE or -IgE-PE,and -B220-APC or -APC-Cy7. For immunized animals, splenocytes
were stained with a cocktail of biotinylated anti-IgG1, -IgG2a-b,
and -IgG3 followed by anti-IgD-FITC, -CD3-FITC, -CD11b-FITC,
-IgM-APC, and SA-PerCP-CY5. Other antibodies used: anti-
Thy1.1-APC and -human CD25a-PECy7 or -APC. All antibodies
were from BDPharmingen or eBioscience. Flow cytometry was per-
formed on a FACSCanto and analyzed with FlowJo (Treestar) analy-
sis software. Values shown for gated populations represent percent-
age of total live lymphocytes based on FSC versus SSC and with
doublet discrimination.
Statistics
When noted, p values were calculated with the Student’s t test.
Retroviral Plasmids and Transduction
Bicistronic, retroviral plasmid backbones used in this work are pMIG
(MSCV-IRES-GFP), pMIT (MSCV-IRES-Thy1.1), and pCSretTAC
(pTAC, MMLV-IRES-huCD25a). Retroviral supernatants for primary
B cell infections were obtained by cotransfecting the packaging
cell line, Phoenix-eco, with a 2:1 ratio of viral plasmid to pCL-ECO
packaging plasmid with Lipofectamine 2000 (Invitrogen) at a 1:2.5
ratio with a coplating protocol (Escobedo and Koh, 2003). For spin-
fections, primary B cells were cultured for 18–24 hr with mitogens
prior to infection. Viral supernatants (1 ml/1 3 106 cells) were incu-
bated with 8 mg/ml polybrene (Sigma) for 10 min on ice prior to addi-
tion to cells and spinfection at 930 3 g for 90 min at 30C. After in-
fection, cells were resuspended in fresh media containing
mitogens with or without PI3K inhibitors.
Western Blot
Western blots of total cell lysates were probed with rabbit anti-phos-
phoAkt (S473) and mouse anti-Akt (Cell Signaling Technologies) and
developed with anti-rabbit AF680 and anti-mouse IR800 (Molecular
Probes). Blots were imaged and band intensities calculated with the
Odyssey Infrared Imaging System (Licor).
QT-PCR
DNase-treated RNA was isolated from GFP+ or Thy1.1+ sorted cells
by the RNeasy method (Qiagen). cDNA was prepared with oligodT-
primed Sprint Advantage Single Shots (Clontech). QT-PCR was per-
formed with SybrGreen (Applied Biosystems) on an ABI Prism7000
under standard conditions with specificity reinforced via the disso-
ciation protocol via published primer sequences (Sayegh et al.,
2003). Relative abundance of mRNA was determined with the rela-
tive quantification method and normalized to Igb message.
Supplemental Data
Six Supplemental Figures can be found with this article online at
http://www.immunity.com/cgi/content/full/25/4/545/DC1/.
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